visualizations
Socinski, Mark A., MD
Overview
overview
- Dr. Mark A. Socinski is a board-certified, fellowship trained medical oncologist, specializing in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. He is an internationally recognized expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small cell lung cancer. His research has focused on incorporating personalized medicine and molecular biomarkers in the treatment of lung cancer. Dr. Socinski formerly served as Co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute. He also serves on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance) and has been instrumental in the development of many cooperative clinical trials. He is the Executive Medical Director of the AdventHealth Cancer Institute.
Affiliation
Member of
-
Research Department
Publications
Most Recent Publications
-
2024
-
2024A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations. ESMO OPEN. 9.Full Text via DOI: 10.1016/j.esmoop.2024.102961 PMID: 38640748
-
2023A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2. ECLINICALMEDICINE. 66.Full Text via DOI: 10.1016/j.eclinm.2023.102317 PMID: 38192592
-
2023Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer. CLINICAL CANCER RESEARCH. 29:4596-4605.Full Text via DOI: 10.1158/1078-0432.CCR-23-1578 PMID: 37702716
-
2023Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked. CLINICAL LUNG CANCER. 24:E242-E246.Full Text via DOI: 10.1016/j.cllc.2023.05.003 PMID: 37451930
-
2023Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS.Full Text via DOI: 10.1007/s13318-023-00855-3 PMID: 37792130
-
2023Correlation of safety and efficacy in atezolizumab therapy across indications. ANNALS OF ONCOLOGY. S1079-S1079.Full Text via DOI: 10.1016/j.annonc.2023.09.815
-
2023Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity. ANNALS OF ONCOLOGY.Full Text via DOI: 10.1016/j.annonc.2023.09.2410
-
2023Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset. TRANSLATIONAL ONCOLOGY. 36.Full Text via DOI: 10.1016/j.tranon.2023.101744 PMID: 37516008
-
2023Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions. JOURNAL OF CLINICAL ONCOLOGY. 41:4218-+.Full Text via DOI: 10.1200/JCO.23.00152 PMID: 37384848
-
2023Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer. FRONTIERS IN ONCOLOGY. 13.Full Text via DOI: 10.3389/fonc.2023.1215524 PMID: 37700839
-
2023Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). JOURNAL OF THORACIC ONCOLOGY. 18:1031-1041.Full Text via DOI: 10.1016/j.jtho.2023.03.016 PMID: 36958688
-
2023Emerging agents for the treatment of advanced or metastatic NSCLC without actionable genomic alterations with progression on first-line therapy. EXPERT REVIEW OF ANTICANCER THERAPY. 817-833.Full Text via DOI: 10.1080/14737140.2023.2235895 PMID: 37486248
-
2023A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. NATURE MEDICINE.Full Text via DOI: 10.1038/s41591-023-02226-6 PMID: 36928816
-
2023Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. CLINICAL CANCER RESEARCH. 29:1047-1055.Full Text via DOI: 10.1158/1078-0432.CCR-22-2323 PMID: 36595566
-
2023Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials. ONCOLOGIST.Full Text via DOI: 10.1093/oncolo/oyad043 PMID: 36905578
-
2023Acquired EGFR Resistant Mutations and Co-mutations in Tumors Of Non-small Cell Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors (TKI). JOURNAL OF THORACIC ONCOLOGY. S3-S3.
-
2023Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine. FRONTIERS IN ONCOLOGY.Full Text via DOI: 10.3389/fonc.2023.1124167 PMID: 37077826
-
2022GEMSTONE-302: "If you keep doing the same thing you get the same result". CHINESE CLINICAL ONCOLOGY.Full Text via DOI: 10.21037/cco-22-103 PMID: 36408544
-
2022A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors. JOURNAL OF IMMUNOTHERAPY. 45:389-395.Full Text via DOI: 10.1097/CJI.0000000000000440 PMID: 36066505
-
2022High activity of poziotinib in G778_P780dup HER2 exon 20 insertion mutations in non-small cell lung cancer (NSCLC). ANNALS OF ONCOLOGY. S1084-S1085.
-
2022Mark A. Socinski, MD, on Progression of Lung Cancer Treatment. ONCOLOGY-NEW YORK. 532-534.
-
2022Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET plus colorectal carcinoma as a unique molecular subset of CRC. ANNALS OF ONCOLOGY. S574-S574.Full Text via DOI: 10.1016/j.annonc.2022.07.105
-
2022The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework. FRONTIERS IN ONCOLOGY. 12.Full Text via DOI: 10.3389/fonc.2022.859892 PMID: 35756655
-
2022A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer. EXPERT OPINION ON INVESTIGATIONAL DRUGS.Full Text via DOI: 10.1080/13543784.2022.2075341 PMID: 35657653
-
2022Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. NATURE MEDICINE.Full Text via DOI: 10.1038/s41591-022-01754-x PMID: 35422531
-
2022Efficacy and safety of poziotinib in treatment-naive HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4. ANNALS OF ONCOLOGY. S13-S13.Full Text via DOI: 10.1016/j.annonc.2022.01.035
-
2022Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. JOURNAL OF CLINICAL ONCOLOGY. 40.Full Text via DOI: 10.1200/JCO.21.01323 PMID: 34843401
-
2022Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. JOURNAL FOR IMMUNOTHERAPY OF CANCER. 10.Full Text via DOI: 10.1136/jitc-2021-003027 PMID: 35190375
-
2022IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. JOURNAL OF THORACIC ONCOLOGY. 17:309-323.Full Text via DOI: 10.1016/j.jtho.2021.09.014 PMID: 34626838
-
2021Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. MOLECULAR CANCER THERAPEUTICS. 20:2577-2584.Full Text via DOI: 10.1158/1535-7163.MCT-21-0201 PMID: 34518295
-
2021Adverse Overall Survival Impact of PD-L1 Positivity in Patients With KRAS G12C Mutation Is Abolished by the Immunotherapy. CLINICAL LUNG CANCER. E856-E858.Full Text via DOI: 10.1016/j.cllc.2021.04.010 PMID: 34119437
-
2021Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC). CLINICAL LUNG CANCER. 22:549-561.Full Text via DOI: 10.1016/j.cllc.2021.05.009 PMID: 34294595
-
2021IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. JOURNAL OF THORACIC ONCOLOGY. 16:1909-1924.Full Text via DOI: 10.1016/j.jtho.2021.07.009 PMID: 34311108
-
2021Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 13.Full Text via DOI: 10.1177/17588359211045845 PMID: 34819997
-
2021Combined Use of CYFRA 21-1, CA125 and CRP Predicts Survival of Metastatic NSCLC Patients With Stable Disease. JOURNAL OF THORACIC ONCOLOGY. S1024-S1025.
-
2021Evaluating Circulating Tumor DNA to Predict Overall Survival Risk in Non-Squamous Non-Small Cell Lung Cancer in IMpower150. JOURNAL OF THORACIC ONCOLOGY. S905-S906.
-
2021Crizotinib in Patients With MET-Amplified NSCLC. JOURNAL OF THORACIC ONCOLOGY. 16:1017-1029.Full Text via DOI: 10.1016/j.jtho.2021.02.010 PMID: 33676017
-
2021A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY.Full Text via DOI: 10.1007/s00432-021-03628-0 PMID: 33866430
-
2021Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. JOURNAL OF THORACIC ONCOLOGY. 16:653-664.Full Text via DOI: 10.1016/j.jtho.2020.11.025 PMID: 33333328
-
2021MET Exnn 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. JCO PRECISION ONCOLOGY. 653-663.Full Text via DOI: 10.1200/PO.20.00516 PMID: 34036238
-
2021A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation. JOURNAL OF THORACIC ONCOLOGY. S695-S696.
-
2021Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer. ANNALS OF ONCOLOGY. S15-S15.Full Text via DOI: 10.1016/j.annonc.2021.01.051
-
2021Updated Efficacy, Safety and Dosing Management of Poziotinib in Previously Treated EGFR and HER2 Exon 20 NSCLC Patients. JOURNAL OF THORACIC ONCOLOGY. S173-S174.
-
2021nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis. FRONTIERS IN ONCOLOGY. 10.Full Text via DOI: 10.3389/fonc.2020.485587 PMID: 33575203
-
2021CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions-A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).. JOURNAL OF CLINICAL ONCOLOGY.Full Text via DOI: 10.1200/JCO.2021.39.3_suppl.TPS449
-
2021Efficacy and safety of poziotinib in treatment-naive NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4). ANNALS OF ONCOLOGY. S1324-S1324.Full Text via DOI: 10.1016/j.annonc.2021.08.2125
-
2021Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer ABOUND.sqm): A Phase III Randomized Clinical Trial. CLINICAL LUNG CANCER. 22:6-+.Full Text via DOI: 10.1016/j.cllc.2020.09.007 PMID: 33097414
-
2021Response to Letter to the Editor.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. e30-e31.Full Text via DOI: 10.1016/j.jtho.2021.02.018 PMID: 33896576
-
2020Final efficacy results from IMpower132: First-line atezolizumab plus chemotherapy in patients with stage IV non-squamous NSCLC. ANNALS OF ONCOLOGY. S1386-S1387.Full Text via DOI: 10.1016/j.annonc.2020.10.369
-
2020Defining high-quality NSCLC care at US cancer centers.. JOURNAL OF CLINICAL ONCOLOGY.
-
2020IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations. ANNALS OF ONCOLOGY. S817-S818.Full Text via DOI: 10.1016/j.annonc.2020.08.1579
-
2020IMpower150: Updated efficacy analysis in patients with EGFR mutations. ANNALS OF ONCOLOGY. S837-S838.Full Text via DOI: 10.1016/j.annonc.2020.08.1607
-
2020Phase III confirmatory efficacy and safety study of proposed bevacizumab biosimilar (MYL-1402O) compared with avastin, in the first-line treatment of patients with stage IV non-squamous non-small cell lung cancer (nsNSCLC). ANNALS OF ONCOLOGY. S883-S884.Full Text via DOI: 10.1016/j.annonc.2020.08.1705
-
2020ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations. ANNALS OF ONCOLOGY. S1188-S1188.Full Text via DOI: 10.1016/j.annonc.2020.08.2293
-
2020Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. JOURNAL OF THORACIC ONCOLOGY. 15:1351-1360.Full Text via DOI: 10.1016/j.jtho.2020.03.028 PMID: 32302702
-
2020Poziotinib activity and durability of responses in previously treated EGFR exon 20 NSCLC patients - a Phase 2 study. CANCER RESEARCH.Full Text via DOI: 10.1158/1538-7445.AM2020-CT081
-
2020Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY. 38:2530-+.Full Text via DOI: 10.1200/JCO.19.03158 PMID: 32459597
-
2020Real-WorldTreatment Patterns andProgression-FreeSurvival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies forALK plus Non-SmallCell Lung Cancer. ONCOLOGIST. 25:867-877.Full Text via DOI: 10.1634/theoncologist.2020-0011 PMID: 32490560
-
2020Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma. CLINICAL LUNG CANCER. 22:E506-E511.Full Text via DOI: 10.1016/j.cllc.2020.07.004 PMID: 32807653
-
2020Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC).. JOURNAL OF CLINICAL ONCOLOGY.
-
2020Gender disparities in hormone positive lung cancer.. JOURNAL OF CLINICAL ONCOLOGY.
-
2020IMpower150: Exploratory analysis of brain metastases development.. JOURNAL OF CLINICAL ONCOLOGY.
-
2020Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer. DRUGS. 883-892.Full Text via DOI: 10.1007/s40265-020-01320-0 PMID: 32436070
-
2020Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.. JOURNAL OF CLINICAL ONCOLOGY.
-
2020What constitutes high-quality NSCLC care? Overarching quality considerations for improving NSCLC care at US cancer centers.. JOURNAL OF CLINICAL ONCOLOGY.
-
2020IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets). PNEUMOLOGIE. S39-S39.Full Text via DOI: 10.1055/s-0039-3403148
-
2020Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy. CANCER. 126:1060-1067.Full Text via DOI: 10.1002/cncr.32573 PMID: 31943168
-
2020Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. ESMO OPEN. 5.Full Text via DOI: 10.1136/esmoopen-2019-000567 PMID: 31958290
-
2019Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. EXPERT REVIEW OF RESPIRATORY MEDICINE. 14:125-136.Full Text via DOI: 10.1080/17476348.2020.1701439 PMID: 31829747
-
2019A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. LUNG CANCER. 136:52-56.Full Text via DOI: 10.1016/j.lungcan.2019.08.009 PMID: 31445354
-
2019IMpower131: Final OS Results of Carboplatin plus Nab-Paclitaxel +/- Atezolizumab in Advanced Squamous NSCLC. JOURNAL OF THORACIC ONCOLOGY. S243-S244.
-
2019Nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Updated Results of the Phase III ABOUND.sqm Study. JOURNAL OF THORACIC ONCOLOGY. S301-S301.
-
2019Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapy. CANCER. 125:2394-2399.Full Text via DOI: 10.1002/cncr.32114 PMID: 30933354
-
2019IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations. SWISS MEDICAL WEEKLY. 14S-14S.
-
2019IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets).. JOURNAL OF CLINICAL ONCOLOGY.
-
2019The prognostic value of KRAS mutation subtypes and PD-L1 expression in patients with lung adenocarcinoma.. JOURNAL OF CLINICAL ONCOLOGY.
-
2019Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. LANCET RESPIRATORY MEDICINE. 7:387-401.Full Text via DOI: 10.1016/S2213-2600(19)30084-0 PMID: 30922878
-
2019
-
2018
-
2018Outcomes of Patients < 70 or >= 70 Years of Age in PACIFIC. JOURNAL OF THORACIC ONCOLOGY. S628-S629.
-
2018Atezolizumab Treatment of Nonsquamous NSCLC REPLY. NEW ENGLAND JOURNAL OF MEDICINE. 1188-1188.PMID: 30231231
-
2018Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. ANNALS OF ONCOLOGY. 1701-1709.Full Text via DOI: 10.1093/annonc/mdy196 PMID: 29905778
-
2018Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. CLINICAL LUNG CANCER. 331-339.Full Text via DOI: 10.1016/j.cllc.2018.03.014 PMID: 29773328
-
2018Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous None-Small-Cell Lung Cancer. CLINICAL LUNG CANCER. 19:E481-E487.Full Text via DOI: 10.1016/j.cllc.2018.03.008 PMID: 29631965
-
2018Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. NEW ENGLAND JOURNAL OF MEDICINE. 378:2288-2301.Full Text via DOI: 10.1056/NEJMoa1716948 PMID: 29863955
-
2018Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. LUNG CANCER. 62-69.Full Text via DOI: 10.1016/j.lungcan.2018.03.025 PMID: 29748017
-
2018A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY.
-
2018
-
2018EGFR Genotyping of Matched Urine, Plasma , and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO PRECISION ONCOLOGY. 2:1-13.Full Text via DOI: 10.1200/PO.17.00116 PMID: 35135111
-
2018Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER. 19:130-+.Full Text via DOI: 10.1016/j.cllc.2017.10.004 PMID: 29158123
-
2018Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. LUNG CANCER. 117:44-49.Full Text via DOI: 10.1016/j.lungcan.2018.01.010 PMID: 29496255
-
2018Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 165-183.Full Text via DOI: 10.1016/j.jtho.2017.11.111 PMID: 29175116
-
2018EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. JOURNAL OF THORACIC ONCOLOGY. 13:228-236.Full Text via DOI: 10.1016/j.jtho.2017.11.109 PMID: 29158193
-
2018PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. MOLECULAR DIAGNOSIS & THERAPY. 22:1-10.Full Text via DOI: 10.1007/s40291-017-0308-6 PMID: 29119407
-
2018A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. JOURNAL OF THORACIC DISEASE. 10:219-227.Full Text via DOI: 10.21037/jtd.2017.12.30 PMID: 29600052
-
2018IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups. ONCOLOGY RESEARCH AND TREATMENT. 239-239.
-
2018Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting.. Journal of clinical pathways : the foundation of value-based care. 49-54.Full Text via DOI: 10.25270/jcp.2018.02.00001 PMID: 31453358
-
2018nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial. DRUG DESIGN DEVELOPMENT AND THERAPY. 12:1445-1451.Full Text via DOI: 10.2147/DDDT.S155750 PMID: 29872267
-
2017Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. RADIOTHERAPY AND ONCOLOGY. 125:293-300.Full Text via DOI: 10.1016/j.radonc.2017.10.001 PMID: 29050957
-
2017Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. JOURNAL OF CLINICAL ONCOLOGY. 35:3591-+.Full Text via DOI: 10.1200/JCO.2017.72.9012 PMID: 28892431
-
2017Phase I/II Trial of Nab-Paclitaxel or Paclitaxel Plus Carboplatin with Concurrent Radiation for Inoperable Stage IIIA/B NSCLC. JOURNAL OF THORACIC ONCOLOGY. S2304-S2304.
-
2017How I Treat Stage IV Non-Small Cell Lung Cancer in the Absence of Any Actionable Oncogenic Driver. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY. 759-765.PMID: 29040255
-
2017Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. LUNG CANCER. 112:195-199.Full Text via DOI: 10.1016/j.lungcan.2017.08.017 PMID: 29191595
-
2017A bioequivalence study of proposed bevacizumab biosimilar, MYL-1402O (A) vs EU-Avastin (B) and US-Avasting (C). ONCOLOGY RESEARCH AND TREATMENT. 163-+.
-
2017Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. JOURNAL OF CLINICAL ONCOLOGY. 35:2885-+.Full Text via DOI: 10.1200/JCO.2016.71.4758 PMID: 28493811
-
2017Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA ONCOLOGY. 3:1043-1050.Full Text via DOI: 10.1001/jamaoncol.2016.6749 PMID: 28208174
-
2017Phase 1/2 Study of Rilotumumab (AMG 102), a Hepatocyte Growth Factor Inhibitor, and Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer. CANCER. 123:2936-2944.Full Text via DOI: 10.1002/cncr.30717 PMID: 28472537
-
2017First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 376:2415-2426.Full Text via DOI: 10.1056/NEJMoa1613493 PMID: 28636851
-
2017B-F1RST: Assessment of novel blood-based biomarkers in patients with first-line advanced or metastatic NSCLC receiving atezolizumab monotherapy. JOURNAL OF CLINICAL ONCOLOGY.Full Text via DOI: 10.1200/JCO.2017.35.15_suppl.TPS9103
-
2017Enhancing clinician confidence on the therapeutic management of non-small cell lung cancer (NSCLC) through continuing medical education (CME).. JOURNAL OF CLINICAL ONCOLOGY.Full Text via DOI: 10.1200/JCO.2017.35.15_suppl.e18271
-
2017IMpower132: A phase III clinical program-1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC.. JOURNAL OF CLINICAL ONCOLOGY.Full Text via DOI: 10.1200/JCO.2017.35.15_suppl.TPS9101
-
2017Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy. JOURNAL OF CLINICAL ONCOLOGY.Full Text via DOI: 10.1200/JCO.2017.35.15_suppl.TPS9105
-
2017Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. JOURNAL OF CLINICAL ONCOLOGY. 35:1387-+.Full Text via DOI: 10.1200/JCO.2016.70.0229 PMID: 28113017
-
2017Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study CALGB 30607 (Alliance). JOURNAL OF THORACIC ONCOLOGY. 12:843-849.Full Text via DOI: 10.1016/j.jtho.2017.01.022 PMID: 28161554
-
2017The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis. CLINICAL LUNG CANCER. 255-258.Full Text via DOI: 10.1016/j.cllc.2016.12.001 PMID: 28188100
-
2017An open-label, phase II study of the polo-like kinase-1 (P1k-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). LUNG CANCER. 104:126-130.Full Text via DOI: 10.1016/j.lungcan.2016.12.019 PMID: 28212994
-
2017Results of a Single Institution Experience with Dose-Escalated Chemoradiation for Locally Advanced Unresectable Non-Small Cell Lung Cancer. FRONTIERS IN ONCOLOGY. 7.Full Text via DOI: 10.3389/fonc.2017.00001 PMID: 28168163
-
2017A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma. JOURNAL OF THORACIC ONCOLOGY. S384-S385.
-
2017A Pooled Analysis Comparing the Outcomes of Elderly to Younger Patients on NCTN Trials of Concurrent CCRT for Stage 3 NSCLC. JOURNAL OF THORACIC ONCOLOGY. S374-S375.
-
2017EGFR FISH as Potential Predictor of Necitumumab Benefit with Chemotherapy in Squamous NSCLC: Subgroup Analyses from SQUIRE. JOURNAL OF THORACIC ONCOLOGY. S955-S956.
-
2017Efficacy and Safety of Necitumumab Continuation Monotherapy in Patients with EGFR-Expressing Tumors in SQUIRE, a Phase 3 Study. JOURNAL OF THORACIC ONCOLOGY. S334-S334.
-
2017First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program. JOURNAL OF THORACIC ONCOLOGY. S1296-S1297.
-
2017Impact of Depth of Response (DpR) on Survival in Patients with Advanced NSCLC Treated with First-Line Chemotherapy. JOURNAL OF THORACIC ONCOLOGY. S387-S388.
-
2017Neratinib Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study. JOURNAL OF THORACIC ONCOLOGY. S358-S359.
-
2017Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. CLINICAL LUNG CANCER. 18:68-76.Full Text via DOI: 10.1016/j.cllc.2016.09.002 PMID: 28341109
-
2017Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. ONCOLOGIST. 22:3-11.Full Text via DOI: 10.1634/theoncologist.2016-0285 PMID: 27821794
-
2017Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. S378-S378.
-
2017Updated Pooled Analysis of CNS Endpoints in Two Phase II Studies of Alectinib in ALK plus NSCLC. JOURNAL OF THORACIC ONCOLOGY. S377-S377.
-
2017nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy. LUNG CANCER-TARGETS AND THERAPY. 8:207-216.Full Text via DOI: 10.2147/LCTT.S138570 PMID: 29138610
-
2016Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. JOURNAL OF THORACIC ONCOLOGY. 2066-2081.Full Text via DOI: 10.1016/j.jtho.2016.08.138 PMID: 27575423
-
2016Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY. 34:4079-+.Full Text via DOI: 10.1200/JCO.2016.68.4639 PMID: 27863201
-
2016ABOUND.PS2 Interim Safety Results: nab-Paclitaxel/Carboplatin Followed by nab-Paclitaxel in NSCLC Patients with ECOG PS of 2. JOURNAL OF THORACIC ONCOLOGY. S274-S274.
-
2016Evaluation of Novel Blood-Based Biomarkers with Atezolizumab Monotherapy in 1L Advanced or Metastatic NSCLC (B-F1RST). JOURNAL OF THORACIC ONCOLOGY. S303-S304.PMID: 27969521
-
2016First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program. JOURNAL OF THORACIC ONCOLOGY. S302-S303.PMID: 27969520
-
2016Paradoxical functions of ZEB1 in EGFR-mutant lung cancer: tumor suppressor and driver of therapeutic resistance. JOURNAL OF THORACIC DISEASE. E1528-E1531.Full Text via DOI: 10.21037/jtd.2016.11.59 PMID: 28066651
-
2016Best Practices in Treatment Selection for Patients With Advanced NSCLC. CANCER CONTROL. 23:2-+.PMID: 27842052
-
2016Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer Secondary Analyses of the ECOG 4599 and PointBreak Trials. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. 39:441-447.Full Text via DOI: 10.1097/COC.0000000000000163 PMID: 25628268
-
2016Clinicopathologic Features of Advanced Squamous NSCLC. JOURNAL OF THORACIC ONCOLOGY. 1411-1422.Full Text via DOI: 10.1016/j.jtho.2016.05.024 PMID: 27296106
-
2016Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR-Expressing Squamous Non-Small-Cell Lung Cancer German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE). ONCOLOGY RESEARCH AND TREATMENT. 39:539-547.Full Text via DOI: 10.1159/000448085 PMID: 27614872
-
2016The Clinical Utility of PD-L1 Testing in Selecting Non-Small Cell Lung Cancer Patients for PD1/PD-L1-Directed Therapy. CLINICAL PHARMACOLOGY & THERAPEUTICS. 212-214.Full Text via DOI: 10.1002/cpt.385 PMID: 27090296
-
2016Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes. CLINICAL LUNG CANCER. 17:367-374.Full Text via DOI: 10.1016/j.cllc.2016.04.002 PMID: 27230605
-
2016Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. ANNALS OF ONCOLOGY. 27:1573-1579.Full Text via DOI: 10.1093/annonc/mdw214 PMID: 27207107
-
2016Immune Checkpoint Blockade in Lung Cancer. DISCOVERY MEDICINE. 22:56-66.PMID: 27585231
-
2016The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial. JOURNAL OF THORACIC ONCOLOGY. 11:808-818.Full Text via DOI: 10.1016/j.jtho.2016.03.002 PMID: 26980471
-
2016Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. LANCET ONCOLOGY. 17:642-650.Full Text via DOI: 10.1016/S1470-2045(16)00077-2 PMID: 27080216
-
2016HSP90 Inhibitors in Lung Cancer: Promise Still Unfulfilled. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY. 14:346-356.PMID: 27379696
-
2016Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes. EUROPEAN JOURNAL OF CANCER. 162-171.Full Text via DOI: 10.1016/j.ejca.2015.12.022 PMID: 26875112
-
2016Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer. CLINICAL LUNG CANCER. 17:128-132.Full Text via DOI: 10.1016/j.cllc.2015.12.006 PMID: 26774201
-
2016Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. LANCET ONCOLOGY. 17:234-242.Full Text via DOI: 10.1016/S1470-2045(15)00488-X PMID: 26708155
-
2015Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction. SEMINARS IN ONCOLOGY. S1-S2.Full Text via DOI: 10.1053/j.seminoncol.2015.09.018 PMID: 26477469
-
2015Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic. SEMINARS IN ONCOLOGY. S19-S28.Full Text via DOI: 10.1053/j.seminoncol.2015.09.017 PMID: 26477471
-
2015Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. CLINICAL CANCER RESEARCH. 21:4321-4326.Full Text via DOI: 10.1158/1078-0432.CCR-14-3281 PMID: 26106072
-
2015Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement. EUROPEAN JOURNAL OF CANCER. S598-S598.
-
2015Updated Efficacy/Safety Data From the Phase 2 NP28761 Study of Alectinib in ALK plus NSCLC. JOURNAL OF THORACIC ONCOLOGY. S237-S238.
-
2015Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. LANCET ONCOLOGY. 16:763-774.Full Text via DOI: 10.1016/S1470-2045(15)00021-2 PMID: 26045340
-
2015Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses.. Annals of oncology : official journal of the European Society for Medical Oncology. 1134-1142.Full Text via DOI: 10.1093/annonc/mdv104 PMID: 25722382
-
2015The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells. CANCERS. 7:876-907.Full Text via DOI: 10.3390/cancers7020814 PMID: 26010604
-
2015The Role of Anti-angiogenesis in Non-small-cell Lung Cancer: an Update. CURRENT ONCOLOGY REPORTS. 17.Full Text via DOI: 10.1007/s11912-015-0448-y PMID: 25947099
-
2015Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER. 16:200-208.Full Text via DOI: 10.1016/j.cllc.2014.11.004 PMID: 25516338
-
2015Clinical considerations for the development of biosimilars in oncology. MABS. 7:286-293.Full Text via DOI: 10.1080/19420862.2015.1008346 PMID: 25621390
-
2015Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. LANCET ONCOLOGY. 16:328-337.Full Text via DOI: 10.1016/S1470-2045(15)70046-X PMID: 25701171
-
2015Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Renal Impairment. CLINICAL LUNG CANCER. 16:112-120.Full Text via DOI: 10.1016/j.cllc.2014.09.003 PMID: 25572008
-
2015Alternative Strategy to Achieve Increased Overall Survival and Better Quality of Life in Patients With Second-Line Advanced Non-Small-Cell Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY. 522-523.Full Text via DOI: 10.1200/JCO.2014.58.1603 PMID: 25584003
-
2015A Randomized Phase II Study of Carboplatin With Weekly or Every-3-Week Nanoparticle Albumin-Bound Paclitaxel (Abraxane) in Patients With Extensive-Stage Small Cell Lung Cancer. ONCOLOGIST. 20:105-106.Full Text via DOI: 10.1634/theoncologist.2014-0327 PMID: 25616430
-
2015Clinicopathologic Features and Outcomes of Patients With Lung Adenocarcinomas Harboring BRAF Mutations in the Lung Cancer Mutation Consortium. CANCER. 121:448-456.Full Text via DOI: 10.1002/cncr.29042 PMID: 25273224
-
2015Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 10:353-359.Full Text via DOI: 10.1097/JTO.0000000000000277 PMID: 25611228
-
2015KRAS mutant lung cancer: progress thus far on an elusive therapeutic target. CLINICAL AND TRANSLATIONAL MEDICINE.Full Text via DOI: 10.1186/s40169-015-0075-0 PMID: 26668062
-
2015Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma. EXPERIMENTAL HEMATOLGY & ONCOLOGY. 4.Full Text via DOI: 10.1186/s40164-015-0029-7 PMID: 26673119
-
2014Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY. 32:4012-U160.Full Text via DOI: 10.1200/JCO.2013.54.5392 PMID: 25385727
-
2014Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. EXPERT OPINION ON PHARMACOTHERAPY. 2693-2708.Full Text via DOI: 10.1517/14656566.2014.971013 PMID: 25381900
-
2014A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy. LUNG CANCER. 86:288-290.Full Text via DOI: 10.1016/j.lungcan.2014.08.011 PMID: 25201721
-
2014Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? The significant impact of chemotherapy in lung cancer.. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY. 767-8.PMID: 25674716
-
2014Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of "Master Protocols" in Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 9:1443-1448.Full Text via DOI: 10.1097/JTO.0000000000000314 PMID: 25521397
-
2014Highlights in NSCLC From the 2014 ASCO Meeting. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY. 12:16-19.PMID: 25768033
-
2014Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer. CURRENT ONCOLOGY. E691-E703.Full Text via DOI: 10.3747/co.21.1997 PMID: 25302040
-
2014Inherited Variation in the ATP-Binding Cassette Transporter ABCB1 and Survival after Chemotherapy for Stage III-IV Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 9:1264-1271.PMID: 25122423
-
2014Erlotinib in African Americans With Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses. CLINICAL PHARMACOLOGY & THERAPEUTICS. 96:182-191.Full Text via DOI: 10.1038/clpt.2014.93 PMID: 24781527
-
2014Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 311:1998-2006.Full Text via DOI: 10.1001/jama.2014.3741 PMID: 24846037
-
2014Metastasis of Breast Carcinoma to the Maxillary Sinus. BREAST JOURNAL. 318-319.Full Text via DOI: 10.1111/tbj.12265 PMID: 24689896
-
2014Assessing Response to Treatment in Non-Small-Cell Lung Cancer: Role of Tumor Volume Evaluated By Computed Tomography. CLINICAL LUNG CANCER. 15:103-109.Full Text via DOI: 10.1016/j.cllc.2013.11.001 PMID: 24361250
-
2014CALGB 30704 (Alliance) A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 9:214-221.Full Text via DOI: 10.1097/JTO.0000000000000071 PMID: 24419419
-
2014Immunotherapy in lung cancer. TRANSLATIONAL LUNG CANCER RESEARCH. 2-14.Full Text via DOI: 10.3978/j.issn.2218-6751.2013.10.13 PMID: 25806276
-
2014Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation. LUNG CANCER. 83:300-301.Full Text via DOI: 10.1016/j.lungcan.2013.11.018 PMID: 24360397
-
2014Patient-Reported Neuropathy and Taxane-Associated Symptoms in a Phase 3 Trial of nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 9:83-90.Full Text via DOI: 10.1097/JTO.0000000000000011 PMID: 24346096
-
2014RET Rearrangements in Lung Adenocarcinoma and Radiation. JOURNAL OF THORACIC ONCOLOGY. 9:118-120.Full Text via DOI: 10.1097/JTO.0000000000000015 PMID: 24346100
-
2014Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. LANCET ONCOLOGY. 15:59-68.Full Text via DOI: 10.1016/S1470-2045(13)70510-2 PMID: 24331154
-
2013Personalizing Therapy in Advanced Non-Small Cell Lung Cancer. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE. 822-836.Full Text via DOI: 10.1055/s-0033-1358552 PMID: 24258572
-
2013PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY. 31:4349-U77.Full Text via DOI: 10.1200/JCO.2012.47.9626 PMID: 24145346
-
2013Phase I Trial of Carboplatin and Etoposide in Combination with Panobinostat in Patients with Lung Cancer. ANTICANCER RESEARCH. 33:4475-4481.PMID: 24123018
-
2013A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). ANNALS OF ONCOLOGY. 24:2382-2389.Full Text via DOI: 10.1093/annonc/mdt212 PMID: 23788751
-
2013Do Oncogenic Drivers Exist in Squamous Cell Carcinoma of the Lung?. ONCOLOGY-NEW YORK. 27:906-+.PMID: 24282989
-
2013Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. ANNALS OF ONCOLOGY. 24:2390-2396.Full Text via DOI: 10.1093/annonc/mdt235 PMID: 23842283
-
2013The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma. CANCER. 119:2268-2274.Full Text via DOI: 10.1002/cncr.28039 PMID: 23526491
-
2013A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer. CLINICAL CANCER RESEARCH. 19:3068-3077.Full Text via DOI: 10.1158/1078-0432.CCR-12-3381 PMID: 23553849
-
2013The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement. CLINICAL CANCER RESEARCH. 19:2629-2636.Full Text via DOI: 10.1158/1078-0432.CCR-12-2935 PMID: 23669423
-
2013Management of Normal Tissue Toxicity Associated With Chemoradiation (Primary Skin, Esophagus, and Lung). CANCER JOURNAL. 231-237.Full Text via DOI: 10.1097/PPO.0b013e31829453fb PMID: 23708070
-
2013Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC Beyond Traditional Treatment Approaches. JOURNAL OF THORACIC ONCOLOGY. 8:587-598.Full Text via DOI: 10.1097/JTO.0b013e318286cf88 PMID: 23546044
-
2013Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST. 143:E341-E368.Full Text via DOI: 10.1378/chest.12-2361 PMID: 23649446
-
2013A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non-Small-Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 8:443-451.Full Text via DOI: 10.1097/JTO.0b013e3182835577 PMID: 23370367
-
2013Safety and efficacy of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.. Annals of oncology : official journal of the European Society for Medical Oncology. 314-321.Full Text via DOI: 10.1093/annonc/mds461 PMID: 23123509
-
2013Validation of Interobserver Agreement in Lung Cancer Assessment: Hematoxylin-Eosin Diagnostic Reproducibility for Non-Small Cell Lung Cancer The 2004 World Health Organization Classification and Therapeutically Relevant Subsets. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE. 137:32-40.Full Text via DOI: 10.5858/arpa.2012-0033-OA PMID: 22583114
-
2012Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. LUNG CANCER. 78:276-281.Full Text via DOI: 10.1016/j.lungcan.2012.09.002 PMID: 23043970
-
2012Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Non-Small-Cell Lung Cancer: Results of a Phase I/II Trial. JOURNAL OF CLINICAL ONCOLOGY. 30:3953-3959.Full Text via DOI: 10.1200/JCO.2012.41.9820 PMID: 23045594
-
2012The Impact of Local and Regional Disease Extent on Overall Survival in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Carcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 84:E385-E392.Full Text via DOI: 10.1016/j.ijrobp.2012.04.045 PMID: 22857887
-
2012Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancer.. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY. 1-16.PMID: 23187688
-
2012Highlights in NSCLC From the 2012 American Society of Clinical Oncology Annual Meeting.. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY. 1-24.PMID: 23072787
-
2012Management of Non-Small Cell Lung Cancer with Oligometastasis. CURRENT ONCOLOGY REPORTS. 14:333-341.Full Text via DOI: 10.1007/s11912-012-0240-1 PMID: 22535505
-
2012Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. ANNALS OF ONCOLOGY. 23:1723-1729.Full Text via DOI: 10.1093/annonc/mdr563 PMID: 22186609
-
2012Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial. JOURNAL OF CLINICAL ONCOLOGY. 30:2063-2069.Full Text via DOI: 10.1200/JCO.2011.40.1315 PMID: 22547605
-
2012Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial. JOURNAL OF CLINICAL ONCOLOGY. 30:2055-2062.Full Text via DOI: 10.1200/JCO.2011.39.5848 PMID: 22547591
-
2012Predicting the need for palliative thoracic radiation after first-line chemotherapy for advanced nonsmall cell lung carcinoma. CANCER. 118:2744-2751.Full Text via DOI: 10.1002/cncr.26495 PMID: 21935913
-
2012Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation. PLOS ONE. 7.Full Text via DOI: 10.1371/journal.pone.0036530 PMID: 22590557
-
2012Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials. LUNG CANCER. 76:222-227.Full Text via DOI: 10.1016/j.lungcan.2011.10.021 PMID: 22115704
-
2011Multitargeted receptor tyrosine kinase inhibition: An antiangiogenic strategy in non-small cell lung cancer. CANCER TREATMENT REVIEWS. 611-617.Full Text via DOI: 10.1016/j.ctrv.2011.04.003 PMID: 21641723
-
2011Personalized Therapy for Non-Small Cell Lung Cancer: Which Drug for Which Patient?. SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY. 23:281-290.Full Text via DOI: 10.1053/j.semtcvs.2012.01.001 PMID: 22443647
-
2011Reinforcement Learning Strategies for Clinical Trials in Nonsmall Cell Lung Cancer. BIOMETRICS. 67:1422-1433.Full Text via DOI: 10.1111/j.1541-0420.2011.01572.x PMID: 21385164
-
2011PULMONARY TOXICITY IN STAGE III NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH HIGH-DOSE (74 GY) 3-DIMENSIONAL CONFORMAL THORACIC RADIOTHERAPY AND CONCURRENT CHEMOTHERAPY FOLLOWING INDUCTION CHEMOTHERAPY: A SECONDARY ANALYSIS OF CANCER AND LEUKEMIA GROUP B (CALGB) TRIAL 30105. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 81:E269-E274.Full Text via DOI: 10.1016/j.ijrobp.2011.01.056 PMID: 21477940
-
2011A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age >= 70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 6:1569-1577.Full Text via DOI: 10.1097/JTO.0b013e3182210430 PMID: 21716146
-
2011Highlights in NSCLC from the American Society of Clinical Oncology Meeting, June 3-7, 2011, Chicago, Illinois, USA.. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY. 1-24.PMID: 22361980
-
2011ALK-Targeted Therapy in NSCLC: Likely to Be of Benefit but Not Quite Ready for Prime Time THE HUSAIN/RUDIN ARTICLE REVIEWED. ONCOLOGY-NEW YORK. 601-607.PMID: 21888259
-
2011Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial. JOURNAL OF CLINICAL ONCOLOGY. 29:2215-2222.Full Text via DOI: 10.1200/JCO.2010.29.3423 PMID: 21502556
-
2011A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 162-171.Full Text via DOI: 10.1016/j.critrevonc.2010.03.003 PMID: 20413322
-
2011A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. LUNG CANCER. 71:151-155.Full Text via DOI: 10.1016/j.lungcan.2010.05.022 PMID: 20580118
-
2011Maintenance Therapy in Advanced Non-small Cell Lung Cancer Current Status and Future Implications. JOURNAL OF THORACIC ONCOLOGY. 174-182.Full Text via DOI: 10.1097/JTO.0b013e318200f9c5 PMID: 21127437
-
2010A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. LUNG CANCER. 70:340-346.Full Text via DOI: 10.1016/j.lungcan.2010.02.011 PMID: 20347506
-
2010Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 5:1977-1985.Full Text via DOI: 10.1097/JTO.0b013e3181f4a5c9 PMID: 20978446
-
2010Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 5:1963-1969.Full Text via DOI: 10.1097/JTO.0b013e3181fd42eb PMID: 21102260
-
2010Personalized Medicine in Non-Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor-Targeted Therapy?. JOURNAL OF CLINICAL ONCOLOGY. 28:4769-4777.Full Text via DOI: 10.1200/JCO.2009.27.4365 PMID: 20921461
-
2010Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types. CLINICAL CANCER RESEARCH. 16:4864-4875.Full Text via DOI: 10.1158/1078-0432.CCR-10-0199 PMID: 20643781
-
2010TARGETED THERAPIES Biomarkers in NSCLC for selecting cetuximab therapy. NATURE REVIEWS CLINICAL ONCOLOGY. 426-428.Full Text via DOI: 10.1038/nrclinonc.2010.99 PMID: 20668478
-
2010A Comparison of White and African American Outcomes from a Three-Arm, Randomized, Phase III Multicenter Trial of Advanced or Metastatic Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 5:993-1000.Full Text via DOI: 10.1097/JTO.0b013e3181e29cf3 PMID: 20593535
-
2010A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 5:852-861.PMID: 20521351
-
2010The Emerging Role of Biomarkers in Advanced Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER. 149-159.Full Text via DOI: 10.3816/CLC.2010.n.019 PMID: 20439190
-
2010If Histology Matters .... JOURNAL OF CLINICAL ONCOLOGY. 1810-1812.Full Text via DOI: 10.1200/JCO.2009.27.1247 PMID: 20212244
-
2010A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. ANNALS OF ONCOLOGY. 21:540-547.Full Text via DOI: 10.1093/annonc/mdp352 PMID: 19833819
-
2010Safety and Efficacy of Combining Sunitinib with Bevacizumab plus Paclitaxel/Carboplatin in Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 5:354-360.Full Text via DOI: 10.1097/JTO.0b013e3181c7307e PMID: 20032789
-
2010The Many Controversies of Stage IIIA/IIIB Lung Cancer The Balmanoukian/Ettinger article reviewed. ONCOLOGY-NEW YORK. 256-259.PMID: 20394137
-
2010Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial. JOURNAL OF CLINICAL ONCOLOGY. 28:744-752.Full Text via DOI: 10.1200/JCO.2009.24.3030 PMID: 20038723
-
2010A Multicenter Phase II Trial of Carboplatin and Cetuximab for Treatment of Advanced Nonsmall Cell Lung Cancer. CANCER INVESTIGATION. 28:208-215.Full Text via DOI: 10.3109/07357900903286958 PMID: 19916742
-
2010Outcomes Associated with Brain Metastases in a Three-Arm Phase III Trial of Gemcitabine-Containing Regimens Versus Paclitaxel Plus Carboplatin for Advanced Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 5:110-116.PMID: 20035187
-
2009Fibroblastic Growth Factor Pathway. JOURNAL OF THORACIC ONCOLOGY. S1066-S1067.PMID: 19861920
-
2009Safety of Bevacizumab in Patients With Non-Small-Cell Lung Cancer and Brain Metastases. JOURNAL OF CLINICAL ONCOLOGY. 27:5255-5261.Full Text via DOI: 10.1200/JCO.2009.22.0616 PMID: 19738122
-
2009Treatment of Surgically Resectable Non-Small-Cell Lung Cancer in Elderly Patients. CLINICAL LUNG CANCER. 405-409.Full Text via DOI: 10.3816/CLC.2009.n.076 PMID: 19900857
-
2009Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. BRITISH JOURNAL OF CANCER. 101:1543-1548.Full Text via DOI: 10.1038/sj.bjc.6605346 PMID: 19826424
-
2009Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY. 27:4787-4792.Full Text via DOI: 10.1200/JCO.2009.23.1548 PMID: 19720897
-
2009Carcinomatous Meningitis in Non-Small-Cell Lung Cancer: Response to High-Dose Erlotinib. JOURNAL OF CLINICAL ONCOLOGY. 27:E31-E32.Full Text via DOI: 10.1200/JCO.2008.21.0963 PMID: 19487379
-
2009Impact of the ASCO 2007 Presentation of HOG Lun 01-24/USO-023 on the Prescribing Plans of American Medical Oncologists for Patients with Stage IIIB Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 4:983-987.PMID: 19561551
-
2009Simultaneous FDG PET+/Glut1+lung and FDG PET-/Glut1-subcarinal lymph node metastases from prostate cancer. ANNALS OF NUCLEAR MEDICINE. 23:595-597.Full Text via DOI: 10.1007/s12149-009-0264-2 PMID: 19437096
-
2009Re-Evaluating Duration of Therapy in Advanced Non-Small-Cell Lung Cancer: Is It Really Duration or Is It More About Timing and Exposure?. JOURNAL OF CLINICAL ONCOLOGY. 3268-3270.Full Text via DOI: 10.1200/JCO.2009.22.4345 PMID: 19470913
-
2009Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER. 10:252-256.Full Text via DOI: 10.3816/CLC.2009.n.035 PMID: 19632943
-
2009A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). ANNALS OF ONCOLOGY. 20:1068-1073.Full Text via DOI: 10.1093/annonc/mdn745 PMID: 19188136
-
2009Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer. CHEST. 135:1588-1595.Full Text via DOI: 10.1378/chest.08-1430 PMID: 19188545
-
2009Current treatments for advanced stage non-small cell lung cancer.. ANNALS OF THE AMERICAN THORACIC SOCIETY. 233-41.Full Text via DOI: 10.1513/pats.200809-110LC PMID: 19349493
-
2009Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). SUPPORTIVE CARE IN CANCER. 17:307-313.Full Text via DOI: 10.1007/s00520-008-0489-y PMID: 18781341
-
2009Treatment Paradigms for Advanced Stage Non-small Cell Lung Cancer in the Era of Multiple Lines of Therapy. JOURNAL OF THORACIC ONCOLOGY. 243-250.PMID: 19179904
-
2009Late Complications of High-Dose (>= 66 GY) Thoracic Conformal Radiation Therapy in Combined Modality Trials in Unresectable Stage III Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 4:74-79.PMID: 19096310
-
2008Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. LANCET. 372:1809-1818.PMID: 19027483
-
2008Pemetrexed in Relapsed Small-Cell Lung Cancer and the Impact of Shortened Vitamin Supplementation Lead-in Time Results of a Phase II Trial. JOURNAL OF THORACIC ONCOLOGY. 3:1308-1316.PMID: 18978567
-
2008Summary statement - Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. JOURNAL OF THORACIC ONCOLOGY. 3:S107-S112.PMID: 18520291
-
2008The current status and evolving role of sunitinib in non-small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY. 3:S119-S123.PMID: 18520293
-
2008Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic Conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. JOURNAL OF CLINICAL ONCOLOGY. 26:2457-2463.Full Text via DOI: 10.1200/JCO.2007.14.7371 PMID: 18487565
-
2008Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies. JOURNAL OF THORACIC ONCOLOGY. 3:521-526.PMID: 18449006
-
2008Bevacizumab as first-line treatment for advanced non-small cell lung cancer. DRUGS OF TODAY. 44:293-301.Full Text via DOI: 10.1358/dot.2008.44.4.1212302 PMID: 18536787
-
2008Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY. 3:250-257.PMID: 18317067
-
2008Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. 26:650-656.Full Text via DOI: 10.1200/JCO.2007.13.9303 PMID: 18235126
-
2008Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer - Cancer and Leukemia Group B study 39901. JOURNAL OF THORACIC ONCOLOGY. 3:158-162.PMID: 18303437
-
2008The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY. 3:145-151.PMID: 18303435
-
2008Considerations for second-line therapy of non-small cell lung cancer. ONCOLOGIST. 13:28-36.Full Text via DOI: 10.1634/theoncologist.13-S1-28 PMID: 18263772
-
2008Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?. ONCOLOGIST. 13:933-944.Full Text via DOI: 10.1634/theoncologist.2008-0019 PMID: 18784157
-
2008Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY. 3:37-45.PMID: 18166839
-
2007Duration of first-line chemotherapy in advanced non-small-cell lung cancer: Less is more in the era of effective subsequent therapies. JOURNAL OF CLINICAL ONCOLOGY. 5155-5157.Full Text via DOI: 10.1200/JCO.2007.13.4015 PMID: 18024862
-
2007Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane((R))) on three treatment schedules in patients with solid tumors. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 60:759-766.Full Text via DOI: 10.1007/s00280-007-0423-x PMID: 17285317
-
2007Limited-stage small-cell lung cancer: The current status of combined-modality therapy. JOURNAL OF CLINICAL ONCOLOGY. 4137-4145.Full Text via DOI: 10.1200/JCO.2007.11.5303 PMID: 17827464
-
2007Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY. 2:819-826.PMID: 17805059
-
2007Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: A meta-analysis. JOURNAL OF THORACIC ONCOLOGY. 2:845-853.PMID: 17805063
-
2007Treatment of non-small cell lung cancer, stage IV - ACCP evidence-based clinical practice guidelines (2nd edition). CHEST. 132:277S-289S.Full Text via DOI: 10.1378/chest.07-1381 PMID: 17873174
-
2007Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. 25:3448-3455.Full Text via DOI: 10.1200/JCO.2006.09.7097 PMID: 17606973
-
2007Antibodies to the epidermal growth factor receptor in non-small cell lung cancer: Current status of matuzumab and panitumumab. CLINICAL CANCER RESEARCH. 13:4597S-4601S.PMID: 17671148
-
2007Novel agents in the treatment of lung cancer: Fourth Cambridge conference. CLINICAL CANCER RESEARCH. 4583S-4588S.PMID: 17671145
-
2007Bevacizumab in the treatment of non-small-cell lung cancer. ONCOGENE. 3691-3698.Full Text via DOI: 10.1038/sj.onc.1210366 PMID: 17530022
-
2007Radiation-induced sarcoma after high-dose thoracic radiation therapy in non-small-cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. 25:1621-1623.Full Text via DOI: 10.1200/JCO.2006.10.3267 PMID: 17443003
-
2007The role of induction therapy for resectable non-small cell lung cancer. DRUGS. 67:321-332.PMID: 17335293
-
2007Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: A Review of Recent Clinical Trials. REVIEWS ON RECENT CLINICAL TRIALS. 117-120.Full Text via DOI: 10.2174/157488707780599401 PMID: 18473996
-
2007Women and lung cancer: Epidemiology, tumor biology, and emerging trends in clinical research. LUNG CANCER. 15-23.Full Text via DOI: 10.1016/j.lungcan.2006.09.008 PMID: 17084482
-
2006Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. JOURNAL OF CLINICAL ONCOLOGY. 5079-5090.Full Text via DOI: 10.1200/JCO.2005.05.1748 PMID: 17075127
-
2006
-
2006Lung cancer presenting with a solitary colon metastasis detected on positron emission tomography scan. JOURNAL OF CLINICAL ONCOLOGY. 24:4939-4940.Full Text via DOI: 10.1200/JCO.2006.06.3354 PMID: 17050879
-
2006Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. 24:4825-4832.Full Text via DOI: 10.1200/JCO.2006.07.4773 PMID: 17050867
-
2006Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. 24:4840-4847.Full Text via DOI: 10.1200/JCO.2006.07.7016 PMID: 17050869
-
2006Treatment of gefitinib-associated folliculitis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 55:710-713.Full Text via DOI: 10.1016/j.jaad.2006.06.034 PMID: 17010757
-
2006Update on nanoparticle albumin-bound paclitaxel.. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY. 745-6.PMID: 17099631
-
2006Combined modality therapy for stage III non-small cell lung cancer. ONCOLOGIST. 11:809-823.PMID: 16880240
-
2006Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer. ANTI-CANCER DRUGS. 17:697-704.PMID: 16917215
-
2006A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer. LUNG CANCER. 52:305-311.Full Text via DOI: 10.1016/j.lungcan.2006.03.002 PMID: 16638621
-
2006Current approaches to advanced-stage non-small-cell lung cancer: First-line therapy in patients with a good functional status. CLINICAL LUNG CANCER. 7:S111-S117.PMID: 16764751
-
2006Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy. LUNG CANCER. 52:67-74.Full Text via DOI: 10.1016/j.lungcan.2005.11.008 PMID: 16499996
-
2006Current and evolving treatment options for limited stage small cell lung cancer. CURRENT OPINION IN ONCOLOGY. 162-172.PMID: 16462186
-
2006Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. LUNG CANCER. 51:237-243.Full Text via DOI: 10.1016/j.lungcan.2005.10.018 PMID: 16378657
-
2006The emergence of a unique population in non-small cell lung cancer: Systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapy. SEMINARS IN ONCOLOGY. S32-S38.Full Text via DOI: 10.1053/j.seminoncol.2005.12.006 PMID: 16472707
-
2006Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: Report from the Cancer and Leukemia Group B. JOURNAL OF CLINICAL ONCOLOGY. 24:407-412.Full Text via DOI: 10.1200/JCO.2005.02.1436 PMID: 16365181
-
2006A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. ANNALS OF ONCOLOGY. 17:104-109.Full Text via DOI: 10.1093/annonc/mdj016 PMID: 16249215
-
2005Seeking new options for the treatment of small-cell lung cancer. LUNG CANCER. 50:S25-S26.PMID: 16291430
-
2005Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. CLINICAL CANCER RESEARCH. 11:5045S-5050S.PMID: 16000612
-
2005Randomized phase III trial comparing cisplatin-etoposide to carhoplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. ANNALS OF ONCOLOGY. 16:1069-1075.Full Text via DOI: 10.1093/annonc/mdi216 PMID: 15860487
-
2005Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy - Comparison of ondansetron, prochlorperazine, and dexamethasone. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. 28:270-276.Full Text via DOI: 10.1097/01.coc.0000145983.35929.2a PMID: 15923800
-
2005Chemotherapeutic issues in the management of unresectable stage III non-small cell lung cancer. SEMINARS IN ONCOLOGY. 32:S18-S24.Full Text via DOI: 10.1053/j.seminoncol.2005.03.006 PMID: 16015532
-
2005Combined modality trials in unresectable stage III non-small cell lung cancer: The cancer and leukemia group B experience. SEMINARS IN ONCOLOGY. 32:S114-S118.Full Text via DOI: 10.1053/j.seminoncol.2005.03.021 PMID: 16015547
-
2005Does more aggressive therapy improve outcomes in the treatment of unresectable stage III non-small cell lung cancer?. SEMINARS IN ONCOLOGY. 32:S13-S17.Full Text via DOI: 10.1053/j.seminoncol.2005.03.005 PMID: 16015531
-
2005Pemetrexed (Alimta) in small cell lung cancer. SEMINARS IN ONCOLOGY. 32:S1-S4.Full Text via DOI: 10.1053/j.seminoncol.2005.02.007 PMID: 15818532
-
2005The evolving role of pemetrexed (Alimta) in lung cancer. SEMINARS IN ONCOLOGY. 32:S16-S22.Full Text via DOI: 10.1053/j.seminoncol.2005.02.008 PMID: 15818533
-
2005A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer. LUNG CANCER. 47:413-419.Full Text via DOI: 10.1016/j.lungcan.2004.08.009 PMID: 15713525
-
2005Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. LUNG CANCER. 47:253-259.Full Text via DOI: 10.1016/j.lungcan.2004.07.040 PMID: 15639724
-
2005A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with carboplatin and etoposide in extensive stage small cell lung cancer. CANCER INVESTIGATION. 23:511-519.Full Text via DOI: 10.1080/07357900500201400 PMID: 16203659
-
2005Bronchial stenosis: An underreported complication of high-dose external beam radiotherapy for lung cancer?. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 61:64-69.Full Text via DOI: 10.1016/j.ijrobp.2004.02.066 PMID: 15629595
-
2004Drug development in patients with advanced non-small cell lung cancer and poor performance status. SEMINARS IN ONCOLOGY. 21-26.Full Text via DOI: 10.1053/j.seminoncol.2004.10.005 PMID: 15599831
-
2004Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. 22:4837-4845.Full Text via DOI: 10.1200/JCO.2004.01.178 PMID: 15570087
-
2004Adjuvant therapy of resected non-small-cell lung cancer.. CLINICAL LUNG CANCER. 162-9.PMID: 15555217
-
2004Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: Report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. JOURNAL OF CLINICAL ONCOLOGY. 22:4329-4340.Full Text via DOI: 10.1200/JCO.2004.02.165 PMID: 15514374
-
2004Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: A dose-escalation phase I trial. JOURNAL OF CLINICAL ONCOLOGY. 22:4341-4350.Full Text via DOI: 10.1200/JCO.2004.03.022 PMID: 15514375
-
2004Management of unresectable stage III non-small cell lung cancer: The role of combined chemoradiation. SEMINARS IN RADIATION ONCOLOGY. 14:326-334.Full Text via DOI: 10.1016/j.semradonc.2004.07.002 PMID: 15558508
-
2004Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. ANNALS OF ONCOLOGY. 15:1033-1041.Full Text via DOI: 10.1093/annonc/mdh282 PMID: 15205196
-
2004Cytotoxic chemotherapy in advanced non-small cell lung cancer: A review of standard treatment paradigms. CLINICAL CANCER RESEARCH. 10:4210S-4214S.PMID: 15217960
-
2004Novel agents in the treatment of lung cancer: Conference summary statement. CLINICAL CANCER RESEARCH. 4199S-4204S.PMID: 15217958
-
2004Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy.. CLINICAL LUNG CANCER. 274-89.PMID: 15086966
-
2003Measuring the side effects of taxane therapy in oncology - The functional assessment of cancer therapy-taxane (FACT-taxane). CANCER. 98:822-831.Full Text via DOI: 10.1002/cncr.11578 PMID: 12910528
-
2003The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer.. Respiratory care clinics of North America. 207-36.PMID: 12911290
-
2003Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 51:328-336.Full Text via DOI: 10.1007/s00280-002-0560-1 PMID: 12721761
-
2003Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer. LUNG CANCER. 40:91-97.Full Text via DOI: 10.1016/S0169-5002(02)00527-5 PMID: 12660013
-
200396-hour paclitaxel infusions: At least 93 hours too long. CANCER INVESTIGATION. 660-662.Full Text via DOI: 10.1081/CNV-120022387 PMID: 14533453
-
2003Chemotherapeutic management of stage IV non-small cell lung cancer. CHEST. 123:226S-243S.PMID: 12527582
-
2003Duration of therapy in advanced, metastatic non-small-cell lung cancer.. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY. 33-8.PMID: 16227958
-
2003Gemcitabine-based combinations as preoperative therapy in resectable non-small-cell lung cancer.. CLINICAL LUNG CANCER. S50-5.PMID: 14720337
-
2002Irinotecan in non-small-cell lung cancer: status of ongoing trials.. Clinical lung cancer. S15-20.PMID: 14659036
-
2002High-dose conformal radiotherapy for treatment of Stage IIIA/IIIB non-small-cell lung cancer: Technical issues and results of a phase I/II trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 54:348-356.PMID: 12243807
-
2002Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated stage IIIB/IV nonsmall cell lung carcinoma. CANCER. 95:1520-1527.Full Text via DOI: 10.1002/cncr.10852 PMID: 12237921
-
2002Second-line, low-dose, weekly paclitaxel in patients with Stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. CANCER. 95:1265-1273.Full Text via DOI: 10.1002/cncr.10835 PMID: 12216094
-
2002Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. 20:1335-1343.PMID: 11870177
-
2002Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation. SEMINARS IN RADIATION ONCOLOGY. 12:59-61.Full Text via DOI: 10.1053/srao.2002.31375 PMID: 11917286
-
2001Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial.. CLINICAL LUNG CANCER. S26-33.PMID: 14725727
-
2001Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing. CANCER CHEMOTHERAPY AND PHARMACOLOGY. 47:373-379.PMID: 11391850
-
2001Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. 19:1078-1087.PMID: 11181672
-
2000Second-line gemcitabine in refractory stage IV non small-cell lung cancer: a phase II trial.. CLINICAL LUNG CANCER. 133-8.PMID: 14731324
-
2000
-
2000Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC.. ONCOLOGY-NEW YORK. 29-34.PMID: 10981288
-
2000Evidence-based medicine in the treatment of non-small-cell lung cancer. CLINICS IN CHEST MEDICINE. 21:107-+.PMID: 10763093
-
2000The role of induction therapy in the management of resectable non-small cell lung cancer.. CANCER CONTROL. 45-55.PMID: 10740660
-
1999Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer. SEMINARS IN ONCOLOGY. 51-61.PMID: 10585009
-
1999The current status of adjuvant chemotherapy for resected non-small cell lung cancer. SEMINARS IN ONCOLOGY. 27-33.PMID: 10566608
-
1999Combined-modality therapy in the nonsurgical management of unresectable stage III non-small cell lung cancer.. Current opinion in pulmonary medicine. 194-200.PMID: 10407686
-
1999Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: Report of a phase II trial. CANCER INVESTIGATION. 17:181-188.PMID: 10099656
-
1999Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer.. ONCOLOGIST. 408-16.PMID: 10551557
-
1998Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients. ANTI-CANCER DRUGS. 9:611-619.PMID: 9773805
-
1998
-
1997High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer.. SEMINARS IN ONCOLOGY. S12.PMID: 9331121
-
1997IIB or not IIB: The current question in staging non-small cell lung cancer. CHEST. 229-234.PMID: 9228381
-
1996Chemotherapy helps patients with advanced non-small cell carcinoma of the lung.. North Carolina medical journal. 281-6.PMID: 8854691
-
1994NEOADJUVANT TREATMENT OF STAGE IIIA NONSMALL CELL LUNG-CANCER - LONG-TERM RESULTS. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. 17:26-36.PMID: 8311004
-
1994CARDIAC SYNOVIAL SARCOMA WITH TRANSLOCATION (X 18) ASSOCIATED WITH ASBESTOS EXPOSURE. CANCER. 73:74-78.PMID: 8275440
-
1991SUCCESSFUL TREATMENT OF DISSEMINATED FUSARIUM INFECTION AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR ACUTE MYELOID-LEUKEMIA. BONE MARROW TRANSPLANTATION. 8:143-145.PMID: 1933056
-
1989ENHANCEMENT OF SUPEROXIDE ANION RELEASE BY GRANULOCYTES HARVESTED FROM PATIENTS RECEIVING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR. BRITISH JOURNAL OF HAEMATOLOGY. 71:475-479.PMID: 2540792
-
1988STAGE-II NONSEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS - AN ANALYSIS OF TREATMENT OPTIONS IN PATIENTS WITH LOW VOLUME RETROPERITONEAL DISEASE. JOURNAL OF UROLOGY. 140:1437-1441.PMID: 2848138
-
1988EFFECT OF RECOMBINANT HUMAN GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR ON CHEMOTHERAPY-INDUCED MYELOSUPPRESSION. NEW ENGLAND JOURNAL OF MEDICINE. 319:593-598.PMID: 3045544
-
1988Radiologic evaluation of nonseminomatous germ cell tumor of the testis.. Seminars in urology. 203-15.PMID: 3244965
-
1988FAILURE PATTERNS OF NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS - RADIOGRAPHIC ANALYSIS OF 51 CASES. RADIOLOGY. 167:641-646.PMID: 2452454
-
1988
-
1988ACUTE-PANCREATITIS ASSOCIATED WITH CHEMOTHERAPY FOR GERM-CELL TUMORS IN 2 PATIENTS. ANNALS OF INTERNAL MEDICINE. 567-568.Full Text via DOI: 10.7326/0003-4819-108-4-567 PMID: 2450502
-
1987DETECTION OF RETROPERITONEAL METASTASES IN EARLY-STAGE NONSEMINOMATOUS TESTICULAR CANCER - ANALYSIS OF DIFFERENT CT CRITERIA. AMERICAN JOURNAL OF ROENTGENOLOGY. 149:1187-1190.PMID: 2825494
-
1985SPECIFIC ANTIBODY-SYNTHESIS INVITRO .3. CORRELATION OF INVIVO AND INVITRO ANTIBODY-RESPONSE TO INFLUENZA IMMUNIZATION IN YOUNG AND OLD SUBJECTS. JOURNAL OF CLINICAL & LABORATORY IMMUNOLOGY. 16:63-67.PMID: 3989855
-
1984INFLUENZA AND AGING - AGE-RELATED-CHANGES AND THE EFFECTS OF THYMOSIN ON THE ANTIBODY-RESPONSE TO INFLUENZA VACCINE. JOURNAL OF CLINICAL IMMUNOLOGY. 4:445-454.PMID: 6334692
-
1984PAINLESS DIARRHEA SECONDARY TO INTESTINAL ISCHEMIA - DIAGNOSIS OF ATHEROMATOUS EMBOLI BY JEJUNAL BIOPSY. DIGESTIVE DISEASES AND SCIENCES. 29:674-677.PMID: 6734375
-
1984PURE RED-BLOOD-CELL APLASIA ASSOCIATED WITH CHRONIC EPSTEIN-BARR VIRUS-INFECTION - EVIDENCE FOR T-CELL-MEDIATED SUPPRESSION OF ERYTHROID COLONY-FORMING-UNITS. JOURNAL OF LABORATORY AND CLINICAL MEDICINE. 104:995-1006.PMID: 6094693
-
1984T-CELLS AND ERYTHROID BURST FORMING UNITS IN CHRONIC LYMPHOCYTIC-LEUKEMIA. AMERICAN JOURNAL OF HEMATOLOGY. 16:149-159.PMID: 6607670
-
1983BRONCHOGENIC CANCER, METASTASES, AND AGING. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY. 31:673-676.PMID: 6630826
-
1983COEXISTENT BREAST AND VAGINAL GRANULOCYTIC SARCOMA. GYNECOLOGIC ONCOLOGY. 16:299-304.PMID: 6578995
-
1983PURE RBC APLASIA AND MYASTHENIA-GRAVIS - COEXISTENCE OF 2 DISEASES ASSOCIATED WITH THYMOMA. ARCHIVES OF INTERNAL MEDICINE. 543-546.PMID: 6338853
Background
Full Name
- Mark A. Socinski, MD
Education
- University of Vermont, Burlington, VT
Residency
- Harvard Medical School/Beth Israel Hospital, Boston
Fellowship
- Harvard Medical School/Beth Israel Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA
Board Certification
- American Board of Internal Medicine
Contact
primary email
- Research.Institute@AdventHealth.com